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Abstract: Cetuximab, a chimeric IgG1 monoclonal antibody that targets the ligand-binding 
domain of the epidermal growth factor receptor (EGFR), is active in metastatic colorectal cancer 
(mCRC). As an IgG1 antibody, cetuximab may exert its antitumor efﬁ  cacy through both EGFR 
antagonism and antibody-dependent cell-mediated cytotoxicity. Clinical trials established the role 
of cetuximab, particularly with irinotecan, in irinotecan-refractory/heavily pretreated patients. 
More recent studies show promising activity in second-line treatment after oxaliplatin-based 
therapy failure, and with ﬁ  rst-line chemotherapy, where increased response rates seen with 
adding cetuximab to ﬁ  rst-line therapy for mCRC may increase chances for curative surgery in 
a population for whom the therapy goal would otherwise be palliative. Cetuximab is generally 
well tolerated; common toxicities are acne-form rash and hypomagnesemia. Rash intensity is 
associated with clinical efﬁ  cacy, and in the future, may be used as a marker for optimal drug 
exposure. Cetuximab activity in mCRC is not correlated with EGFR expression, and consequently 
other markers will be needed to identify the most likely responders. Cetuximab has clinically 
emerged as a core agent, along with 5-ﬂ  uorouracil, irinotecan, oxaliplatin, and bevacizumab, for 
overall mCRC management to optimize survival. Ongoing studies are exploring best combina-
tions of cetuximab with these other agents to maximize patient outcome.
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Introduction
The introduction of irinotecan (Camptosar®, Pharmacia and Upjohn Co, New York, 
NY), oxaliplatin (Eloxatin®, sanoﬁ  -aventis U.S. LLC, Bridgewater, NJ), and biolog-
ics over the last decade has yielded incremental improvements in survival of patients 
with metastatic colorectal cancer (mCRC). Both irinotecan and oxaliplatin improved 
efﬁ  cacy when added to 5-ﬂ  uoruracil (5-FU) in ﬁ  rst-line therapy (Douillard et al 2000; 
Saltz et al 2000) and in pretreated patients (Cunningham et al 1998; Rougier et al 
1998; de Gramont et al 2000). It has also been shown that oxaliplatin plus 5-FU–based 
therapy (FOLFOX) and irinotecan plus 5-FU–based therapy (FOLFIRI) can be used 
sequentially, regardless of order, resulting in median survival times reaching 21 months 
(Tournigand et al 2004). A pooled analysis of 11 phase III trials found that median 
survival was signiﬁ  cantly correlated with the percentage of patients who received all 
3 cytotoxic agents (5-FU, irinotecan, and oxaliplatin) at some point in the course of 
treatment (p = 0.0001), regardless of the sequence in which they were used (Grothey 
et al 2004; Grothey and Sargent 2005). These ﬁ  ndings form the basis for the current 
paradigm in mCRC management: 5-FU, irinotecan, and oxaliplatin should be admin-
istered at some point during the course of treatment, typically starting with either 
oxaliplatin or irinotecan in combination with 5-FU.
Clinical outcome has been further improved by incorporating biologics into this 
treatment paradigm. Bevacizumab (Avastin®, Genentech, Inc South San Francisco, 
CA) is an anti-angiogenic monoclonal antibody directed against vascular endothelial Biologics: Targets & Therapy 2007:1(2) 78
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growth factor (VEGF), which improved response rate, as well 
as progression-free survival (PFS) and median survival by 
4.4 and 4.7 months, respectively, when added to irinotecan 
plus 5-FU in ﬁ  rst-line therapy, (Hurwitz et al 2004) and by 
2.4 and 2.1 months, respectively, when added to FOLFOX 
after irinotecan failure (Giantonio et al 2007). The value 
of adding bevacizumab to irinotecan following FOLFOX 
failure, or continuing bevacizumab therapy after failure of a 
bevacizumab-containing regimen is not fully established. The 
recent report from the retrospective Bevacizumab Regimens 
Investigation of Treatment Effects and Safety (BRiTE) study 
suggests that continued use of bevacizumab may provide a 
meaningful clinical advantage in terms of long-term survival 
(Grothey et al 2007); however, this approach is currently 
under investigation in the prospective SWOG 0600 and 
BOND 2.5 trials. Bevacizumab has very little activity when 
used alone or in combination with 5-FU in refractory disease 
(Chen et al 2006; Giantonio et al 2007).
Biologics targeting the epidermal growth factor receptor 
(EGFR) have shown consistently activity in mCRC. The 
EGFR mediates cell proliferation, differentiation, migra-
tion, and adhesion, and enhances processes critical to tumor 
growth and progression, including angiogenesis, apoptosis 
inhibition, tumor invasiveness, and metastatic spread (Lenz 
2006). EGFR is overexpressed in many colorectal tumors; 
although some studies have shown inconsistent ﬁ  ndings, the 
levels of EGFR expression are related to prognosis, with 
higher expression levels correlating with shorter survival 
times and greater metastatic potential (Nicholson et al 
2001; Spano et al 2005). The chimeric IgG1 monoclonal 
antibody cetuximab (ERBITUX, ImClone Systems Incorpo-
rated, New York, NY and Bristol-Myers Squibb Company, 
Princeton, NJ) was the ﬁ  rst biologic directed against EGFR 
to receive approval by the FDA for use in mCRC. This 
article focuses on the clinical efﬁ  cacy and tolerability of 
cetuximab, and discusses its role in the management of 
mCRC. Another anti-EGFR biologic – the human IgG2 
monoclonal antibody panitumumab (VectibixTM, Amgen 
Inc., Thousand Oaks, CA) has only recently arrived on the 
market, but comprehensive data with this agent, including a 
demonstration of survival beneﬁ  t in mCRC, or feasibility as 
part of therapeutic combinations, are still lacking (Wainberg 
and Hecht 2006).
Cetuximab: Mechanism of action 
and pharmacology
The EGFR is a 170-kD transmembrane glycoprotein, which is 
a member of the ErbB family of receptors, and is sometimes 
referred to as ErbB1 or HER1 (Wells 1999; Vallbohmer and 
Lenz 2005a). It consists of a ligand-binding extracellular 
domain, a lipophilic transmembrane region, and an intracel-
lular tyrosine kinase domain. Binding of endogenous ligands, 
such as epidermal growth factor and transforming growth 
factor-α, promotes EGFR homo- or hetero-dimerization, 
leading to activation and autophosphorylation of tyrosine 
residues in the receptor’s intracellular domain. As a result, 
adapter proteins such as Grb2, Ras-specific GTPase-
activating protein (GAP), and phosphatidylinositol-3-kinase 
(PI-3K), can interact with the phosphotyrosine residues and 
stimulate downstream signaling, including the Ras-MAPK 
and PI-3K-Akt pathways. The nature of the EGFR ligand as 
well as the coreceptor involved in dimerization determines 
which signaling pathways are activated and the ﬁ  nal cellular 
response (Yarden and Sliwkowski 2001).
Target-speciﬁ  c mechanisms
Cetuximab binds speciﬁ  cally to the extracellular domain 
of EGFR as a competitive antagonist of the endogenous 
ligands (Harding and Burtness 2005). Cetuximab binding 
promotes internalization of the EGFR, effectively leading 
to downregulation of EGFR on the cell surface. Together, 
these effects block EGFR-mediated signaling leading to 
cell cycle arrest in G1, and pro-apoptotic processes (Huang 
et al 1999; Kiyota et al 2002; Harding and Burtness 2005). 
EGFR-dependent transcriptional programs are also affected 
by cetuximab, which reduces angiogenesis, tumor invasive-
ness, and metastatic spread (Harding and Burtness 2005).
Preclinical studies showed that cetuximab acts synergisti-
cally with various cytotoxic agents to augment tumor growth 
inhibition (Huang et al 1999; Overholser et al 2000). Such 
effects have been observed with topotecan (Hycamtin®, 
GlaxoSmithKline, Research Triangle Park, NC) (Ciardiello 
et al 1999), and more importantly, with irinotecan (Prewett 
et al 2002). Notably, the cetuximab-irinotecan combination 
also produced growth inhibition of irinotecan-refractory 
DLD-1 and HT-29 xenografts, whereas tumor growth was not 
controlled by either agent alone. On histological examination, 
the combination of cetuximab and irinotecan led to extensive 
tumor necrosis, reduced tumor cell proliferation, increased 
tumor cell apoptosis, and decreased tumor vasculature.
Cetuximab also enhances radiosensitivity (Huang et al 
1999). The EGFR can be activated in a ligand-independent 
manner, which results in cell cycle arrest and initiation 
of DNA repair mechanisms. However, in the presence of 
cetuximab, EGFR nuclear import and subsequent activation 
of DNA repair mechanisms after radiation exposure were Biologics: Targets & Therapy 2007:1(2) 79
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inhibited, and radiosensitivity was enhanced (Dittmann et al 
2005). Taken together, these preclinical studies illustrate that 
cetuximab restores chemosensitivity to cytotoxic agents and 
also enhances sensitivity to radiation therapy.
Immune-mediated mechanisms
As an IgG1 monoclonal antibody, cetuximab also has the 
potential to kill tumor cells through antibody-dependent 
cell-mediated cytotoxicity (ADCC). The specificity of 
cetuximab for the EGFR is determined by its antigen-binding 
region, whereas its Fc region is characteristic of other IgG1 
immunoglobulins. After binding to EGFR, the Fc region of 
cetuximab remains exposed, and may be recognized by Fcγ 
receptors (FcγR) on natural killer cells and other immune 
effectors (Iannello and Ahmad 2005). In general, FcγRs bind 
effectively to IgG1 and IgG3 antibodies, only moderately to 
IgG4 antibodies, but poorly to IgG2 antibodies (Goldsby et al 
2003). Thus, an IgG1 monoclonal antibody like cetuximab 
would be more likely to stimulate ADCC as compared to 
IgG2 antibodies (such as panitumumab). Cetuximab has 
been shown to promote ADCC against tumor cell lines, with 
activity tending to increase with higher EGFR expression 
(Kawaguchi et al 2007; Kurai et al 2007).
ADCC is regulated by several different FcγR isoforms, 
including FcγRIIIa in natural killer cells and FcγRIIa in mac-
rophages. Studies based on the clinical effect of the genetic 
polymorphisms identiﬁ  ed in both receptor isoforms have 
helped provide proof of principle of the clinical relevance of 
ADCC (van Sorge et al 2003). These receptor polymorphisms 
have different afﬁ  nities for their target Fc domains, which 
would be expected to translate into different levels of ADCC 
activity, and ultimately impact clinical response. Indeed, 
seminal studies with the IgG1 rituximab in patients with 
follicular lymphoma showed that certain polymorphisms 
(FcγRIIIa-158V and FcγRIIa-131H) were independently 
associated with higher response rates and longer PFS (Weng 
and Levy 2003; Cartron et al 2004).
Whether ADCC actually contributes to the clinical 
efﬁ  cacy of cetuximab, however, remains to be determined. 
Zhang and colleagues (Zhang et al 2007) recently explored 
whether FcγRIIa and FcγRIIIa polymorphisms would inﬂ  u-
ence the clinical response to single-agent cetuximab in a 
cohort of 39 mCRC patients who had previously failed 
irinotecan and oxaliplatin therapy. Analysis of the rates of 
clinical beneﬁ  t (stable disease or partial response) as well as 
median PFS and overall survival favored patients with the 
FcγRIIa-131H/H and H/R genotypes relative to those with the 
R/R genotype, as well as patients with FcγRIIIa-158F/F and 
F/V genotypes relative to those with the V/V-genotype. When 
the 2 polymorphisms were considered together, patients with 
either FcγRIIIa-158V/V or FcγRIIa-116R/R genotype had 
signiﬁ  cantly shorter PFS than the remaining patients (1.1 
vs 3.7 months, p = 0.004) and tended to have shorter overall 
survival as well (2.3 vs 10.7 months, p = 0.093) (Figure 1). 
These ﬁ  ndings support the potential contribution of ADCC 
to the clinical efﬁ  cacy of cetuximab in mCRC, but they 
differ from the results obtained with rituximab (Rituxan®, 
Genentech, Inc., South San Francisco, CA and Biogen Idec 
Inc., Cambridge, MA) in follicular lymphoma. This raises the 
possibility that solid tumors respond differently than hemato-
logical malignancies to ADCC, particularly when comparing 
late-stage solid tumors with ﬁ  rst-line treatment of lymphoma. 
Additional studies are needed to better deﬁ  ne the clinical 
signiﬁ  cance of ADCC to the efﬁ  cacy of cetuximab.
As knowledge about the role of EGFR in tumor growth 
and progression continues to advance, it will provide a better 
understanding about which mechanisms of cetuximab are 
important in conveying clinical beneﬁ  t in mCRC as well as 
in other solid malignancies.
Clinical efﬁ  cacy
Following the pattern of activity observed in xenograft mod-
els, cetuximab was initially investigated in combination with 
cytotoxic agents, particularly irinotecan. To date, that combina-
tion remains the most effective cetuximab-based therapy for 
patients with mCRC disease who have received prior therapy. 
Numerous single-arm and randomized studies recently com-
pleted or nearing completion are generating a more complete 
proﬁ  le of cetuximab as part of non-irinotecan-based combina-
tions, as well as in untreated patients with mCRC. In parallel, 
and beyond the scope of this review, cetuximab has also been 
proven effective in head and neck cancers and non-small cell 
lung cancers (Rosell et al 2004; Bonner et al 2006; Kelly et al 
2006; Vermorken et al 2007).
Early clinical studies in refractory mCRC
The initial clinical evaluation of cetuximab in mCRC was 
performed in patients who had been previously treated 
with irinotecan (Table 1). Although these studies were not 
comparative, they provided an important framework for 
the clinical development of this agent, and warranted its 
regulatory approval both in North America and the EU. 
Cetuximab was administered at an initial dose of 400 mg/m2 
and then weekly at 250 mg/m2. This regimen has remained 
the standard whether cetuximab is given in monotherapy or 
in combination with other agents.Biologics: Targets & Therapy 2007:1(2) 80
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Saltz and colleagues (Saltz et al 2004) evaluated 
single-agent cetuximab in 57 patients with EGFR-positive 
mCRC who had failed previous irinotecan-based therapy. 
Partial responses were achieved in 5 patients (9%), whereas 
minor responses or stable disease were seen in an additional 
20 patients (35%). The median time to tumor progression was 
1.4 months, and median survival from the start of cetuximab 
therapy was 6.4 months. More recently, Lenz and co-workers 
(Lenz et al 2006) administered single-agent cetuximab to 346 
patients with EGFR-positive mCRC refractory to irinotecan, 
oxaliplatin, and ﬂ  uoropyrimidines. Forty patients (12%) 
had partial responses and an additional 110 patients (32%) 
had stable disease. The median survival was 6.6 months 
(95% CI: 5.6–7.6 months), with 27.4% of the study cohort 
surviving at 1 year.
These studies demonstrated the activity of cetux-
imab as a single agent. The most efﬁ  cacious modality of 
cetuximab therapy in refractory mCRC, however, is the 
combination with irinotecan. Cunningham and colleagues 
(Cunningham et al 2004) randomly assigned 329 patients 
with EGFR-expressing mCRC who had failed a previous 
irinotecan-based regimen in a 2:1 ratio to treatment with 
cetuximab plus irinotecan or cetuximab alone. Irinotecan 
was given at the same dose and schedule as in the regimen 
that the patient had previously failed. Patients receiving 
the combination of cetuximab and irinotecan had signiﬁ  -
cantly higher response rates (23% vs 11%, p = 0.007) and 
disease control rates (56% vs 32%, p   0.001), and a longer 
median time to progression (4.1 vs 1.5 months, p   0.001) 
than those who received single-agent cetuximab. Notably, 
cetuximab showed comparable activity in the subset of 
206 patients who had previously failed both irinotecan and 
oxaliplatin: the response rate was 22% with cetuximab plus 
irinotecan as compared to 9% with cetuximab alone (p = 
0.01). Median survival, however, did not differ signiﬁ  cantly 
between treatment groups, although it was numerically 
longer for those receiving cetuximab and irinotecan (8.6 
vs 6.9 months). Consistent results with cetuximab-based 
combinations have been reported by single-arm studies. 
Saltz and colleagues (Saltz et al 2001) reported a response 
rate of 17% with combination cetuximab and irinotecan in 
a study of 127 patients with irinotecan-refractory mCRC, 
and Souglakos and coworkers (Souglakos et al 2007) have 
reported a response rate of 20% with cetuximab added to 
capecitabine (Xeloda® Roche Laboratories Inc, Nutley, 
NJ)-oxaliplatin therapy in patients with oxaliplatin- and 
irinotecan-refractory mCRC.
These results have been obtained mostly in heavily 
pretreated patients (for instance, although the Cunningham 
study required only prior irinotecan for eligibility, over 
70% of patients had received 2 prior therapies or more), but 
illustrates several points that have paved the way for the 
0 3 6 91 2
Months Since Start of Cetuximab Therapy
Log-rank  P value = 0.004
FCGamma 2A: H/H or H/R and
FCGamma 2A: R/R or
FCGamma 3A V/V (n=13)



























































Figure 1 Effect of FcγR polymorphisms on PFS in patients with refractory mCRC treated with single-agent cetuximab. Patients with either the FcγIIa-R/R or FcγIIIa-V/V 
genotypes had signiﬁ  cantly shorter PFS than those with other genotypes. Reprinted with permission from Zhang W, Gordon M, Schultheis A, et al 2007. FCGR2A and 
FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent 
cetuzimab. J Clin Oncol, 25:3712–18. Copyright © 2006 Americal Society of Clinical Oncology.Biologics: Targets & Therapy 2007:1(2) 81
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current development trajectory of cetuximab in mCRC, and 
its incorporation in earlier therapy settings (Cunningham et al 
2004). First, the cetuximab-irinotecan combination is among 
the most active regimens in pretreated patients. Second, the 
greater activity of this combination relative to single-agent 
cetuximab, even in patients refractory (never responsive) 
to irinotecan, suggests that chemosensitivity to irinotecan 
may be restored when it is administered in combination with 
cetuximab. Third, cetuximab exhibited comparable activity in 
patients who had received irinotecan as in those treated with 
both irinotecan and oxaliplatin, suggesting that it maintains 
its efﬁ  cacy in mCRC across later lines of therapy. Finally, 
in these studies, the degree of EGFR expression – whether 
deﬁ  ned by the percentage of EGFR-expressing cells or by 
the maximal staining intensity per cell – did not correlate 
with the clinical activity of cetuximab (Cunningham et al 
2004; Lenz et al 2006). Moreover, Chung and co-workers 
(Chung et al 2005) retrospectively identiﬁ  ed 16 irinotecan-
refractory mCRC patients with EGFR-negative tumors who 
received cetuximab within the ﬁ  rst 3 months of its com-
mercial availability. Fourteen patients were treated with 
cetuximab in combination with irinotecan, and the other 2 
patients with cetuximab alone. Overall, 4 patients (25%) 
responded to treatment, consistent with the response rate 
reported for patients with EGFR-positive tumors in the phase 
II trials described above. These ﬁ  ndings indicate that EGFR 
expression is not a valid criterion for selecting patients for 
cetuximab therapy, and underscore the need for selective 
biomarkers that can predict which patients are most likely 
to respond to cetuximab.
Single-agent cetuximab vs BSC 
in multi-refractory patients
As a conﬁ  rmation of the role of single-agent cetuximab as 
standard salvage therapy after multiple treatments, a recently 
reported phase III has demonstrated the survival beneﬁ  t 
associated with cetuximab treatment, over best supportive 
care (BSC), in multi-refractory patients. The National 
Cancer Institute of Canada (NCIC) Clinical Trials Group in 
conjunction with the Australasian Gastro-Intestinal Trials 
Group conducted a phase III trial (NCIC 017) to compare 
single-agent cetuximab with BSC in a total of 572 patients 
with EGFR-expressing mCRC who had previously been 
treated with 5-FU or another thymidylate synthase inhibi-
tor, and who had failed irinotecan and oxaliplatin (Jonker 
2007). Patients were stratiﬁ  ed by study center and Eastern 
Cooperative Oncology Group (ECOG) performance status 
(0–1 vs 2), and then randomly allocated to cetuximab plus 
BSC or BSC alone. The primary study endpoint was overall 
survival. Overall, 82% of the patients had received at least 
3 previous chemotherapy regimens. Cetuximab produced a 
signiﬁ  cantly higher objective response rate than BSC alone 
(6.6% vs 0%; p   0.0001), and also allowed more patients 
to achieve stable disease (29.6% vs 10.2%). Importantly, 
the addition of cetuximab to BSC signiﬁ  cantly improved 
median survival compared with BSC alone (6.1 vs 4.6 
Table 1 Phase II studies of cetuximab in EGFR-Expressing refractory mCRC (Saltz et al 2001; Saltz et al 2004; Cunningham et al 2004; 
Lenz et al 2006b; Souglakos et al 2007)
Study  Therapy  Pts (N)  Tumor refractory  PR (%)  SD (%)  MDR (mo)  Median  MS (mo)
     to       TTP  (mo) 
Saltz et al 2004  Cetuximab  57  Irinotecan  10.5  35.1  4.2  1.4  6.4
Lenz 2006  Cetuximab  346  Irinotecan,   11.6  31.8  4.2  1.4a 6.6
      oxaliplatin, and 5-FU         
Saltz et al 2001  Cetuximab/  121  Irinotecan  17.4  30.6  2.8  NR  NR
  Irinotecan           
Cunningham et al  Cetuximab  111  Irinotecan  10.8  21.6  4.2  1.5  6.9
2004 Cetuximab/  218    22.9  32.6  5.7  4.1  8.6
 Irinotecan      (p  = 0.007)     (p    0.001) (p  = 0.48)
Cunningham et al  Cetuximab  71  Irinotecan and   8.5  NR  NR  NR  NR
2004b Cetuximab/  135  oxaliplatin  22.2      
 Irinotecan      (p  = 0.01)      
Souglakos et al  Cetuximab/  40  Irinotecan and   20c 53  4.9  2.9  10.7
2007  Capecitabine/   oxaliplatin        
  Oxaliplatin           
aMedian progression-free survival.
bSubgroup analysis.
cIncludes 1 patient with complete response (2.5%).
Abbreviations: PR, partial response; SD, stable disease; MDR, median duration of response; TTP, time to progression; MS, median survival.Biologics: Targets & Therapy 2007:1(2) 82
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months; HR = 0.77; 95% CI: 0.64–0.92; p = 0.005), and 
also signiﬁ  cantly improved the time to tumor progression 
(HR = 0.68; 95% CI: 0.57–0.80; p   0.0001). Notably, 
these effects of cetuximab remained statistically signiﬁ  cant 
even after adjusting for potential prognostic factors that were 
speciﬁ  ed in the study protocol (p = 0.014 and p = 0.0002, 
respectively). Thus, NCIC 017 conﬁ  rms the efﬁ  cacy of 
single-agent cetuximab in multi-refractory mCRC patients, 
and is the ﬁ  rst study to demonstrate a survival beneﬁ  t associ-
ated with an anti-EGFR agent in this setting.
Cetuximab plus irinotecan after FOLFOX 
failure
As discussed above, by the time of FDA (and EMEA) 
approval of cetuximab, the combination with irinotecan had 
been proven to be effective after irinotecan failure; however, 
bona-ﬁ  de comparative data documenting the additive con-
tribution of cetuximab to this regimen were lacking. The 
Erbitux Plus Irinotecan in Colorectal Cancer (EPIC) study 
was designed to compare cetuximab plus irinotecan versus 
irinotecan alone in second-line treatment of irinotecan-naïve 
mCRC patients after failure of previous ﬁ  rst-line FOLFOX 
therapy (Sobrero 2007). Single-agent irinotecan was used 
as comparator, as it was the standard of care in this setting 
at the time EPIC was initiated. A total of 1298 patients with 
EGFR-positive mCRC were stratiﬁ  ed by study site and 
ECOG performance status, and then randomly assigned 
to receive cetuximab plus irinotecan or irinotecan alone. 
Irinotecan was administered at a dose of 350 mg/m2 every 
3 weeks, and cetuximab was given at its standard dose 
(400 mg/m2 initially and then 250 mg/m2 weekly). Adding 
cetuximab to irinotecan was superior to irinotecan alone, as 
it signiﬁ  cantly improved PFS (4.0 vs 2.6 months; HR = 0.69; 
95% CI: 0.62–0.78; p   0.0001) and produced a higher 
response rate (16.4% vs 4.2%; p   0.0001). Importantly, 
adding cetuximab to irinotecan did not exacerbate toxicity, 
except for acne-form rash.
Despite the positive results for the secondary endpoints, 
however, the primary study point, overall survival, was not 
met. Median survival was comparable between treatments 
(10.7 vs 10.0 months; HR = 0.975; 95.03% CI: 0.85–1.11; 
p = 0.71), tempering, at ﬁ  rst glance, the positive conclusions 
that could be drawn from the secondary endpoint results. This 
lack of difference, however, is a likely consequence of the 
imbalances in post-trial therapy. As cetuximab plus irinotecan 
were adopted as the standard of care after irinotecan failure, 
nearly half of the patients (approximately 40%) allocated to 
the comparator arm went on to receive this combination (the 
de facto experimental treatment in the study) once they left 
the protocol after progression (Sobrero 2007).
Beyond the interpretation of these results in terms of 
cetuximab efﬁ  cacy, this study also highlights the ongoing 
challenges of clinical trial design and endpoint selection in a 
fast evolving area such as mCRC. While prolonging survival 
is unarguably the most relevant clinical goal, it is debatable 
whether median survival provides an accurate measure of 
clinical efﬁ  cacy, versus PFS, for an agent given in ﬁ  rst-line or 
second-line treatment of mCRC. Depending on the therapeu-
tic setting, the reliability of median survival as an endpoint 
may be confounded by signiﬁ  cant factors beyond the control 
of a trial design, whereas PFS is more likely to reﬂ  ect only 
protocol-controlled variables, and is sufﬁ  cient for showing 
the clinical advantage of one regimen over another.
Adding cetuximab to ﬁ  rst-line mCRC 
treatment
Building upon the effectiveness of cetuximab in refractory 
mCRC, several studies have also been conducted to explore 
whether adding cetuximab to first-line therapy would 
improve patient outcome (Table 2). In the CRYSTAL trial, 
cetuximab was added to the FOLFIRI regimen, one of the 
possible standards of care for ﬁ  rst-line treatment. A total of 
1220 patients with untreated EGFR-expressing mCRC were 
randomly assigned to cetuximab plus FOLFIRI or FOLFIRI 
alone. A top-line report from the ﬁ  nal results of CRYSTAL, 
recently presented at the 48th annual ASCO meeting, 
indicated that adding cetuximab to FOLFIRI signiﬁ  cantly 
prolonged PFS (from 8.0 months to 8.9, p = 0.036), and 
increased response rates (from 38.7% to 46.9%, p = 0.005) 
compared to FOLFIRI alone (Van Cutsem 2007). Of par-
ticular interest is the beneﬁ  t derived by patients with liver 
disease only, whose rates of R0 resectability increased by 3 
fold with the addition of cetuximab. These ﬁ  ndings infer that 
cetuximab is active in the ﬁ  rst-line setting, and especially 
valuable for patients with synchronous liver disease, but it 
is difﬁ  cult to extrapolate them to current clinical practice 
in the United States, where practice patterns strongly favor 
FOLFOX plus bevacizumab as ﬁ  rst-line treatment.
Furthermore, several smaller trials in which cetuximab 
was added to ﬁ  rst-line FOLFOX have produced promising 
results. Andre and colleagues (Andre et al 2007) admin-
istered cetuximab in combination with the FOLFOX-4 
regimen (oxaliplatin 85 mg/m2 on day 1, plus folinic acid 
200 mg/m2 and 5-FU in a 400 mg/m2 bolus followed by a 
continuous infusion of 600 mg/m2 for 22 hours on days 1 
and 2 every 2 weeks) to 43 patients with EGFR-positive Biologics: Targets & Therapy 2007:1(2) 83
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mCRC. Objective responses were conﬁ  rmed in 33 patients 
(77%). Median PFS was 12 months, and median survival 
was 30 months (95% CI: 17.8 to 33.8 months) after a median 
follow-up of 30.5 months. Notably, 10 patients (23%) with 
initially unresectable metastases (8 liver, 1 lung, and 1 adre-
nal) subsequently underwent surgery with curative intent, 
with complete resections achieved in 9 of these cases. No 
unexpected toxicities were seen. Initial results from the ran-
domized phase II OPUS trial (Bokemeyer 2007) comparing 
FOLFOX with or without cetuximab in 337 patients with 
untreated mCRC, are consistent with these encouraging 
observations, demonstrating a difference in response rates 
favoring cetuximab (45.6% vs 35.7%). Folprecht and col-
leagues (Folprecht et al 2006) reported comparable results 
in a study of 21 patients with EGFR-expressing mCRC who 
received cetuximab in combination with weekly irinotecan 
and low-dose or high-dose infusional 5-FU. Median survival 
was 33 months, and 4 patients (19%) underwent potentially 
curative surgery.
The CALGB 80203 study was designed to compare 
ﬁ  rst-line FOLFIRI versus FOLFOX, both with and without 
cetuximab. Enrollment to this study, however, could not 
be completed due to the fast adoption of bevacizumab as 
a component of ﬁ  rst-line therapy. The study was closed 
to accrual after a total of 238 of the planned 2200 patients 
were enrolled. Preliminary results showed that response 
rates were higher in the arms with cetuximab, particularly 
when it was administered with FOLFOX: 60% for FOLFOX 
plus cetuximab; 40% for FOLFOX alone; 44% for FOLFIRI 
plus cetuximab; and 36% for FOLFIRI alone. Overall, adding 
cetuximab signiﬁ  cantly increased response rates compared 
to treatment without cetuximab (52% vs 38%; p = 0.029). At 
the time of the report, the median follow-up was 16 months, 
still too early to tell whether adding cetuximab improved 
PFS (Venook et al 2006b). The ongoing OPUS study is 
also evaluating whether adding cetuximab to FOLFOX-4 
will improve response rates, and secondarily whether it will 
allow more patients to undergo potentially curative surgery 
for metastases, and prolong the duration of response, PFS, 
and overall survival (Bokemeyer 2005).
Combination of biologics
Another promising avenue of therapeutic development 
for cetuximab in mCRC could bring together the activity 
of the 2 biologic agents effective in CRC, cetuximab and 
bevacizumab, based on a strong mechanistic rationale. The 
EGFR pathway controls the production of VEGF (and other 
angiogenic factors) in cells, targeting both markers may 
therefore have a greater antitumor effect. The feasibility of 
administering these 2 monoclonal antibodies in combination 
was addressed in the BOND-2 study, focusing on patients 
otherwise candidates for cetuximab therapy. In this phase II 
trial, 74 patients with irinotecan-refractory mCRC were ran-
domly assigned to treatment with cetuximab, bevacizumab, 
and irinotecan, or to cetuximab and bevacizumab (Saltz et al 
2005). These patients had not been treated previously with 
cetuximab or bevacizumab, and were not required to have 
EGFR-expressing tumors. Bevacizumab was administered 
at a dose of 5 mg/kg every other week, and irinotecan was 
given in the same dose and schedule as last given prior to 
Table 2 Clinical studies of cetuximab in ﬁ  rst-line treatment of EGFR-expressing mCRC (Folprecht et al 2006;  Venook et al 2006b; 
Van Cutsem 2007;  Andre et al 2007)
Study  Treatment  Patients  OR (%)  SD (%)  PFS (mo)  OS (mo)
CRYSTAL FOLFIRIa 609  38.7  NR  8  NR
  FOLFIRI + cetuximab  608  46.9    8.9 
Andre et al 2007  FOLFOX-4b + cetuximab  43  77  18  12.3  30.0 (17.8, 33.8)
CALGB 80203c FOLFIRIa 61  36  38  8.4  NR
  FOLFIRI + cetuximab  59  44  32  10.6 
 FOLFOXd 60  40  30  9.8 
  FOLFOX + cetuximab  58  60  26  8.2 
Folprecht et al 2007  Irinotecan/5-FUe + cetuximab  21  67  29  9.9  33 (20 to ?)
aFOLFIRI consisted of irinotecan 180 mg/m2, folinic acid 400 mg/m2, and 5-FU in a 400 mg/m2 bolus followed by a continuous infusion of 2400 mg/m2 for 46 hours every 
2 weeks (Lang et al 2006; Venook et al 2006b).
bFOLFOX-4 consisted of oxaliplatin 85 mg/m2 on day 1, plus folinic acid 200 mg/m2, and 5-FU in a 400 mg/m2 bolus followed by a continuous infusion of 600 mg/m2 for 
22 hours on days 1 and 2 every 2 weeks (Andre et al 2007).
cPreliminary results.
dFOLFOX consisted of oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, and 5-FU in a 400 mg/m2 bolus followed by a continuous infusion of 2400 mg/m2 for 46 hours every 
2 weeks (Venook et al 2006b).
eIrinotecan 80 mg/m2, folinic acid 500 mg/m2, and 5-FU as a 1500 mg/m2 (n = 6) or 2000 mg/m2 (n = 15) continuous infusion for 24 hours weekly for 6 weeks every 50 days 
(Folprecht et al 2007).
Abbreviations: OR, overall response; SD, stable disease; PFS, progression-free survival; OS, overall survival.Biologics: Targets & Therapy 2007:1(2) 84
Lenz
study entry. Notably, as observed in the initial BOND study 
by Cunningham et al (2004) (see above), the addition of 
irinotecan results in greater activity in these patients who 
had already progressed after one irinotecan-containing 
regimen. Furthermore, adding bevacizumab increased the 
response rate and prolonged the time to progression relative 
to historical controls treated with cetuximab/irinotecan or 
cetuximab alone in this setting (Table 3) (Saltz et al 2005). 
The observed toxicities were consistent with those of the 
individual agents, with no evidence that adding bevacizumab 
enhanced toxicity. Pharmacogenomic analysis revealed 
several polymorphisms of genes involved in angiogenesis, 
the EGFR pathway, and DNA repair that may be potential 
markers for clinical outcome in mCRC patients receiving 
both biologics (Lenz et al 2007). Thus, results from BOND-2 
are hypothesis-generating and provide preliminary evidence 
of the clinical beneﬁ  t of combining cetuximab and bevaci-
zumab in bevacizumab-naïve patients. The BOND2.5 and 
SWOG 0600 trials are exploring these same combinations in 
bevacizumab-refractory patients (Saltz et al 2005).
The next step is the investigation of the cetuximab-
bevacizumab doublet in untreated patients, for whom 
bevacizumab is already part of standard treatment. CALGB/
SWOG 80405 is designed to determine the optimal combi-
nation of these biologics in ﬁ  rst-line treatment of mCRC. 
Patients and their physicians will ﬁ  rst choose either the 
FOLFOX or FOLFIRI chemotherapy regimen and then will 
be randomized to treatment with cetuximab, bevacizumab, or 
both. The primary endpoint in this study is overall survival, 
with response rate, PFS, duration of response, and time to 
progression as secondary endpoints. Additionally, this study 
will explore which regimen is most likely to allow patients to 
undergo potentially curative surgery of metastases following 
chemotherapy. Planned accrual is 2,289 patients (Venook 
et al 2006a). The CAIRO2 trial, sponsored by the Dutch 
Colorectal Cancer Group, is another randomized phase III 
trial, which is evaluating whether adding cetuximab to a 
regimen of capecitabine, oxaliplatin, and bevacizumab will 
improve PFS relative to the same regimen without cetuximab 
in previously untreated mCRC patients. Planned accrual is 
750 patients (Punt 2005). In the context of the recent results 
obtained with the IgG2 antibody panitumumab in similar 
combinations, the outcome from these trials is now crucial to 
understand the feasibility of simultaneous EGFR and VEGF 
inhibition in untreated patients. In the phase III Panitumumab 
Advanced Colorectal Cancer Evaluation (PACCE) trial 
investigating FOLFOX/bevacizumab with or without pani-
tumumab, an interim analysis revealed no beneﬁ  t with the 
addition of this antibody to the bevacizumab/chemotherapy 
regimen; furthermore, the trial was closed early due to the 
increased toxicity of the dual targeted combination, with 
unacceptable rates of pulmonary embolism, diarrhea, dehy-
dration and infections (Amgen press release 2007).
It is likely that some patients may beneﬁ  t more from 
FOLFOX plus bevacizumab, others from FOLFIRI plus 
cetuximab, and still others from different combinations of 
chemotherapy and biologics. The key will be to identify 
factors (see below) that predict which patients will respond 
best to which regimen.
Earlier use of cetuximab in the course 
of disease: the perioperative setting
The impact of cetuximab improving response rates in 
patients with metastatic disease may also become extremely 
important, as it has the potential to dramatically change 
the therapeutic outlook of certain patients. Preliminary 
data suggest that use of cetuximab in untreated mCRC 
may “downstage” unresectable patients and allow potentially 
curative surgery of metastases. For example, as described 
previously, R0 resectability rates reached 23% in unselected 
patients treated with cetuximab and FOLFOX-4, and 25% in 
patients treated with cetuximab plus 5FU/irinotecan regimens 
(Folprecht 2006; Andre et al 2007).
Ongoing studies are exploring whether cetuximab may 
be useful earlier in the course of disease in the adjuvant and 
neoadjuvant settings. Hofheinz and colleagues (Hofheinz 
et al 2006) showed that adding cetuximab to neoadjuvant 
capecitabine, irinotecan, and radiation therapy is feasible in 
patients with locally advanced rectal cancer. Of 19 patients 
who underwent resection, nodal downstaging was found in 
12 patients and T-stage downstaging in 8 patients. Complete 
Table 3 Effect of adding bevacizumab to cetuximab/irinotecan 
and cetuximab in irinotecan-Refractory mCRC patients: com-
parison of BOND-2 results with historical controls (Saltz et al 
2005)
 Response    Time  to 
 rate    progression
 %  p-value  Months  p-value
Cetuximab/irinotecan 38  0.03  8.5   0.01
+ bevacizumab       
Cetuximab/irinotecan   23    4.0   
(historical control)   
Cetuximab +  23  0.05  6.9   0.01
bevacizumab 
Cetuximab 11    1.5    
(historical control)   Biologics: Targets & Therapy 2007:1(2) 85
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tumor regression was achieved in 5 patients, with only 
microfoci within ﬁ  brotic tissue found in 6 others. Similarly, 
Machiels and co-workers (Machiels et al 2007) found down-
staging in pathological classiﬁ  cation in 14 of 37 patients 
(38%) with advanced or metastatic rectal cancer following 
neoadjuvant treatment with cetuximab, capecitabine, and 
radiation. From a mechanistic as well as safety perspective, 
cetuximab may be an optimal agent for use in the peri-surgical 
setting, in that EGFR is not involved in liver regeneration, and 
cetuximab does not interfere with wound healing.
Alternative dosing schedules
Cetuximab is still given on a weekly basis when used in 
combination with bi-weekly chemotherapy regimens, such as 
FOLFIRI and FOLFOX, but additional alternative schedules 
can be optimized to make cetuximab administration more 
ﬂ  exible, and perhaps easier to coordinate with those cytotoxic 
regimens. The standard regimen of cetuximab is 400 mg/m2 
initially followed by 250 mg/m2 weekly. However, because 
of its long elimination half-life – 4–5 days at steady-state 
(ERBITUX PI 2007) – it is possible to administer cetuximab 
every 2 weeks and thereby improve patient convenience. 
Tabernero and colleagues (Tabernero et al 2006) reported 
preliminary results from a phase I study, in which 20 mCRC 
patients received cetuximab 400 or 500 mg/m2 every 2 weeks 
for 6 weeks in monotherapy and then in combination with 
FOLFIRI. No dose-limiting toxicities were reported. At steady-
state, the pharmacokinetics of cetuximab 500 mg/m2 every 2 
weeks were comparable to those achieved with the standard 
once weekly regimen. Preliminary results showed no major 
differences between the 2 schedules in terms of inhibition of 
EGFR signaling in skin.
Pfeiffer and colleagues (Pfeiffer et al 2007) subsequently 
evaluated a biweekly regimen of cetuximab and irinotecan 
as third-line therapy in 40 consecutive patients with multi-
refractory mCRC. Cetuximab was administered at an initial 
loading dose of 400 mg/m2 followed 1 week later by 250 
mg/m2 and then biweekly by a 500 mg/m2 infusion over 
100 minutes. Irinotecan 180 mg/m2 was also administered 
biweekly starting 30 minutes after completion of the cetux-
imab infusion. The bi-weekly cetuximab-irinotecan regimen 
produced a response rate of 23%, with a median time to 
progression of 4.7 months. Median survival had not been 
reached after a median follow-up of 6 months. These results 
strongly indicate that bi-weekly administration of cetuximab 
is feasible and does not compromise efﬁ  cacy. Nonetheless, 
further evaluation of the bi-weekly cetuximab regimen is 
needed before it can be routinely used in clinical practice.
Predictive markers
As the clinical trials discussed above have shown, the 
reﬁ  nement of patient selection is one area in the clinical 
development of cetuximab that still requires further study. 
The initial clinical trials of cetuximab enrolled patients with 
EGFR-positive mCRC based on immunohistochemical 
analysis, but results have demonstrated that clinical responses 
and survival were independent of EGFR expression. Not only 
there are tumors who respond even without detectable pres-
ence of the EGFR, there is a substantial portion of patients 
who do not respond, even when their tumors express the 
EGFR at high levels. This underscores the need to identify 
factors that can predict response or resistance to cetuximab 
therapy. Recent studies have identiﬁ  ed potential predictive 
factors, although neither has been used to prospectively select 
patients for a clinical trial. Accordingly, it is too early to 
determine the value of these factors in clinical practice.
Lievre and coworkers (Lievre et al 2006) recently 
reported that tumors with mutations in the K-Ras gene are 
associated with resistance to cetuximab therapy. In their 
study, 11 of 30 patients (37%) responded to cetuximab 
therapy, which was mostly given in combination with irino-
tecan alone (75%) and in a multi-refractory setting (80%). 
None of the patients who responded to cetuximab, but 13 
of the 19 nonresponders, had tumors with a mutated K-Ras 
gene (p = 0.0003). Similar results have been reported by 
Di Fiore et al (Di Fiore et al 2007) and De Roock et al (De 
Roock et al 2007). These studies found K-Ras mutations to 
be predictive of resistance to cetuximab in 59 and 37 patients 
respectively. All responders to cetuximab harbored wild-type 
K-Ras in their tumors while no responses were observed in 
patients with tumors bearing mutant versions of the K-Ras 
gene; in addition, Di Fiore et al (Di Fiore et al 2007) were 
able to document a signiﬁ  cant association between K-ras 
mutations and shorter time to progression (3 months vs 5.5 
months for wild-type K-ras, p = 0.015).
Vallböhmer and colleagues (Vallbohmer et al 2005b) eval-
uated whether mRNA expression of EGFR and 4 other genes 
involved in EGFR signaling (cyclin D1, cyclooxygenase-2, 
VEGF, and IL-8) were associated with clinical outcome to 
single-agent cetuximab in a cohort of 39 patients with mCRC 
refractory to irinotecan and oxaliplatin. The expression of 
VEGF was the only factor predictive of response to cetux-
imab, with higher gene expression predicting progressive 
disease (p = 0.038). None of the factors individually predicted 
survival in the study cohort, although the combination of 
low expression of EGFR, cyclooxygenase-2, and IL-8 was 
associated with signiﬁ  cantly longer survival relative to high Biologics: Targets & Therapy 2007:1(2) 86
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levels of expression of any of these genes (13.5 vs 2.3 months; 
p = 0.028). These associations were independent of skin 
toxicity, which also correlates with response to cetuximab 
and will be discussed in detail in a later section.
With these data in hand, it is tempting to speculate, for 
instance, that patients with K-Ras mutations should receive 
a non-cetuximab regimen (ie, with bevacizumab), and those 
without such mutations should be treated with a cetuximab-
based regimen. At the moment, there are no methods to make 
these decisions reliably.
More comprehensive pharmacogenomic approaches have 
also been undertaken. A recent report indicated that, in addi-
tion to K-RAS mutation being an indicator of resistance, high 
levels of the EGFR ligands epiregulin and amphiregulin cor-
related with response (Khambata-Ford 2007). Tools that will 
allow incorporating these results into the clinic are eagerly 
awaited, as they may greatly enhance treatment decisions 
and ultimately patient outcomes.
Tolerability
Dermatologic toxicity
Acne-form rash is associated with all EGFR inhibitors and 
is the most frequent toxicity associated with cetuximab. The 
frequency of acne-form rash reported in the large phase III 
trials of cetuximab in mCRC was 78% to 88%, with most of 
these events of grade 1 or 2 intensity according to National 
Cancer Institute Common Toxicity Criteria (Jonker et al 
2007; Sobrero et al 2007). Approximately 10% of the cases 
were severe. The rash is characterized by an erythematous 
pustular/papular appearance, and has a distribution similar 
to that of acne vulgaris, in that it typically involves the upper 
body (face, neck, scalp, chest, and upper back) but rarely 
the extremities (Lenz 2006; Hu et al 2007). Pruritus, nail 
disorders, and abnormal hair growth may also be present. The 
rash typically appears within the ﬁ  rst 2–3 weeks of cetuximab 
therapy, later peaks in intensity, and subsequently fades or 
resolves during continued treatment (Lenz 2006).
In general, mild rash is easily managed with conven-
tional skin-care measures (such as emollients, mild soaps), 
and in more moderate cases, by adding topical and/or oral 
antibiotics, and if pruritus is present, an antihistamine 
as well (ERBITUX PI 2006; Hu et al 2007). Severe rash 
may require a reduction in cetuximab dose. Patients who 
develop dermatological toxicities should be monitored for 
the development of infectious or inﬂ  ammatory sequelae, and 
appropriate treatment provided should they occur (ERBITUX 
PI 2006). To date, there have been no reports of severe septic 
complications with cetuximab-related rash.
This particular toxicity seems to be intimately linked to 
the biologic activity of cetuximab. The EGFR is expressed on 
epidermal keratinocytes and hair follicles, and is thought to 
play a role in maintaining skin integrity and follicular homeo-
stasis (Lenz 2006; Hu et al 2007). Accordingly, blocking 
these effects may be responsible for the acne-form eruptions 
and its follicular localization. Importantly, the intensity of the 
acne-form rash has been associated with the clinical efﬁ  cacy 
of cetuximab, suggesting that it may be a surrogate marker for 
its antitumor activity (Perez-Soler and Saltz 2005).
To investigate this possibility, the EVEREST study randomly 
assigned irinotecan-refractory mCRC patients who had no or 
mild skin reactions after the ﬁ  rst 3 weeks of cetuximab and 
irinotecan therapy to either continue on the standard cetuximab 
regimen (ie, 250 mg/m2 weekly) or to receive escalating cetux-
imab doses in combination with irinotecan. In this latter arm, the 
dose of cetuximab was increased in 50 mg/m2 increments every 
2 weeks until grade 3 toxicity developed, a tumor response was 
achieved, or a maximum dose of 500 mg/m2 was reached. A 
total of 166 patients were enrolled; 89 patients were randomized 
to the study protocol, and the remaining 77 patients who were 
ineligible for randomization (mostly due to the presence of grade 
2 or greater skin toxicity after the ﬁ  rst 3 weeks) were followed 
on the standard regimen (Van Cutsem et al 2007).
In the dose escalation arm, 24 of 44 patients (55%) reached 
the maximal cetuximab dose of 500 mg/m2. Grade 3 skin reac-
tions were more common in the dose escalation group than in 
those allocated to the standard regimen (9% vs 0%), and similar 
to the frequency in the group ineligible for randomization (12%). 
As hypothesized, the response rate was higher in the dose escala-
tion group than in those allocated to standard cetuximab (30% 
vs 13%), and comparable to the response rate in those ineligible 
for randomization with grade 2 or greater skin toxicity (34%). 
Other grade 3/4 toxicities (eg, diarrhea, fatigue, abdominal pain, 
and hypomagnesemia) were slightly higher in the dose escala-
tion group, possibly reﬂ  ecting the longer treatment duration 
rather than the higher cetuximab dose (Van Cutsem et al 2007). 
EVEREST shows that dose escalation to 500 mg/m2 is feasible 
in patients who do not initially develop intense rash, producing a 
higher incidence of grade 3 skin reactions, which correlates with 
an increase in response rates. EVEREST, therefore, provides 
further evidence of the relationship between skin toxicity and 
clinical efﬁ  cacy.
Infusion reactions
Infusion reactions may occur during therapy with monoclonal 
antibodies and cytotoxics (Lenz 2006). In clinical trials, severe 
infusion reactions have occurred in 3% of patients treated with Biologics: Targets & Therapy 2007:1(2) 87
Cetuximab in colorectal cancer
cetuximab, with approximately 90% of these episodes occurring 
during administration of the ﬁ  rst cetuximab dose, (ERBITUX 
PI 2006) although in the more recent reports, the incidence of 
severe infusion reactions has dropped to 1.5% (Sobrero 2007). 
Severe infusion reactions are characterized by a rapid onset of 
an anaphylactic-like presentation (airway obstruction, urticaria, 
hypotension, and/or cardiac arrest) and require immediate inter-
ruption of the cetuximab infusion and discontinuation from 
further treatment. Because some patients may experience severe 
infusion reactions later in the course of treatment, patients should 
be monitored for at least 1 hour after all cetuximab infusions, and 
for even longer periods in those with milder reactions (ERBITUX 
PI 2006). Appropriate medical interventions, including epineph-
rine, corticosteroids, intravenous antihistamines, bronchodila-
tors, and oxygen, should be kept readily available, and their use 
considered depending of the severity of the reaction.
The management of infusion reactions is consistent with 
that for other infusional agents. Premedication with intrave-
nous diphenhydramine 50 mg or an equivalent antihistamine 
is recommended before cetuximab infusion (ERBITUX PI 
2006). Because antihistamines may cause drowsiness, fatigue, 
bradyarrhythmias, and other side effects, most early clinical 
trials of cetuximab gave study investigators discretion in use of 
premedication after the ﬁ  rst dose. Chung and colleagues (Chung 
et al 2007) conducted a retrospective analysis of all patients 
treated with cetuximab at Memorial Sloan-Kettering Cancer 
Center (MSKCC) outside of a clinical trial during the ﬁ  rst 28 
months that the drug was commercially available (February 
2004 to June 2006). A total of 453 patients were identiﬁ  ed, all 
of whom received 50 mg of diphenhydramine before the ﬁ  rst 
cetuximab dose and 25 mg before the second dose, consistent 
with institutional guidelines. Severe infusion reactions occurred 
in 7 patients (1.5%) – all during the ﬁ  rst infusion – and grade 1 
or 2 reactions occurred in 17 patients (4%), which were charac-
terized by mild dyspnea, rigors, fever, and/or ﬂ  ushing. Each of 
these reactions occurred after diphenhydramine premedication. 
The remaining 429 patients did not experience any infusion reac-
tions during the ﬁ  rst 2 cetuximab doses with diphenhydramine 
premedication nor during a total of 4138 cetuximab infusions 
administered without diphenhydramine premedication. This 
study suggests that diphenhydramine premedication can be 
eliminated after the ﬁ  rst 2 cetuximab doses, without negatively 
affecting patients’ safety.
Hypomagnesemia
Hypomagnesemia is a relatively common side effect, which 
may occur in up to 50% of patients treated with cetuximab 
(ERBITUX PI 2006). Because serum magnesium is often 
not measured, this side effect may be frequently missed, 
and only become apparent after it becomes severe. Clinical 
manifestations of hypomagnesemia may occur gradually or 
suddenly, and include cardiac arrhythmias, seizures, and 
other electrolyte abnormalities (eg, hypokalemia) (Whang 
et al 1994; Iannello and Belﬁ  ore 2001). Certain patients, such 
as those with a pre-existing history of cardiac arrhythmias, 
warrant close monitoring for this toxicity.
The frequency of hypomagnesemia during treatment of 
mCRC with cetuximab has been evaluated retrospectively at 
2 cancer centers. Schrag and colleagues (Schrag et al 2005) 
reviewed serum chemistry reports from 154 consecutive colorec-
tal cancer patients treated with cetuximab at MSKCC. Only 34 
patients had at least 1 serum magnesium measurement during 
cetuximab treatment, and of these, 6 patients (18%) had grade 
3, and 2 patients (6%) had grade 4 hypomagnesemia, character-
ized by serum magnesium levels  0.9 mg/dL and  0.7 mg/dL, 
respectively. Similarly, Fakih and co-workers (Fakih et al 2006) 
reviewed the charts of 114 patients treated with cetuximab at 
the Roswell Park Cancer Institute. Overall, 48 patients had 
normal magnesium levels before cetuximab treatment, and a 
repeat measurement of magnesium during treatment. Of these, 
13 patients (27%) developed grade 3 or 4 hypomagnesemia 
during cetuximab therapy, with the incidence rising from 6% 
among those treated for  3 months to 47% in those treated  6 
months. Accordingly, serum magnesium should be monitored 
during cetuximab therapy, and electrolyte replacement pro-
vided as needed (ERBITUX PI 2006). It is important to note 
that this effect may persist for 4 weeks or longer after therapy 
discontinuation.
Development of hypomagnesemia may be related to 
inhibition of EGFR in the kidneys, although it may also be 
a consequence of diarrhea (Lenz 2006). Most of the ﬁ  ltered 
load of magnesium is reabsorbed in the thick ascending 
loop of Henle, with a smaller percentage reabsorbed in 
the proximal and distal tubules. Because EGFR is highly 
expressed in the apical membrane of the loop of Henle, it 
raises the possibility that blocking EGFR could interfere with 
magnesium transport in this region of the nephron (Schrag 
et al 2005). Nevertheless, regulation of serum magnesium 
also depends on gastrointestinal absorption, and an effect 
of EGFR inhibition on this process cannot be excluded at 
the present time.
Practical and patient-related issues
Quality of life
Another important aspect in the practical application of 
cetuximab therapy in mCRC, where the therapeutic goals Biologics: Targets & Therapy 2007:1(2) 88
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are palliative, is the assessment of its effect on quality of 
life. That effect may provide a complementary insight on 
cetuximab’s therapeutic proﬁ  le. The European Organization 
for Research and Treatment of Cancer (EORTC) QLQ-30 
quality of life questionnaire was incorporated into the phase 
III studies, including NCIC 017 and EPIC (Jonker et al 2007; 
Sobrero et al 2007). In NCIC 017, cetuximab signiﬁ  cantly 
slowed the deterioration in physical function (p   0.046) 
and global health status (p   0.008) relative to BSC when 
measured after 8 and 16 weeks of treatment. Similarly, in 
EPIC, cetuximab plus irinotecan was more effective than 
irinotecan alone in maintaining quality of life, with signiﬁ  -
cant differences between treatments in multiple symptom 
scales, including fatigue (p = 0.005), pain (p   0.001), 
and nausea and vomiting (p   0.001), as well as in global 
health status (p = 0.047) and in 4 of the 5 functional scales, 
including physical (p = 0.002), role (p = 0.003), emotional 
(p = 0.002), and cognitive functioning (p   0.001). Therefore, 
the improvement in overall activity seen with cetuximab in 
these studies was accompanied by better maintenance of 
quality of life.
Adverse event management
The visibility of skin toxicity may impact the patient’s 
acceptance of cetuximab therapy. Some patients may refuse 
to continue cetuximab therapy for esthetic reasons once 
severe skin rash appears, particularly when inﬂ  uenced by 
social or environmental circumstances. This underscores 
the importance of managing the patient’s expectations, and 
conveying the fact that skin toxicity may subside during 
continued treatment with cetuximab and eventually resolves 
without permanent scarring, also, it may be seen in a positive 
light due to its association with clinical efﬁ  cacy.
Although cetuximab is generally well tolerated, potential 
life-threatening events such as infusion reactions may occur. 
Accordingly, physicians and their staffs should be prepared 
to handle these emergencies by monitoring patients during 
and for at least 1 hour after each cetuximab infusion, and by 
having appropriate interventions readily available should 
they be needed. In addition, attention should be paid to 
monitoring patients for electrolyte abnormalities that could 
evolve into potentially serious adverse events (ERBITUX 
PI 2006).
Nonetheless, the toxicity proﬁ  le of cetuximab does not 
overlap with that of cytotoxic agents, making it an appealing 
agent for use in combination regimens. As our understanding 
of cetuximab’s proﬁ  le (and that of other biologics) grows, 
these toxicity considerations will perhaps play a role in 
tailoring long-term individual treatment plans. Because 
cetuximab enhances the efﬁ  cacy of chemotherapy, it may 
be possible to justify a break in chemotherapy for those 
who respond to treatment while continuing maintenance 
therapy with cetuximab or another biologic, an approach 
currently under investigation. This may provide patients with 
a “toxicity” break while off chemotherapy.
Conclusions
Cetuximab has been used effectively in patients with refrac-
tory mCRC, and its role in management of colorectal cancer 
is growing. Recent clinical studies show that cetuximab 
has promising activity in second-line, and the adoption of 
cetuximab plus irinotecan as one of the standard options in 
that setting has been acknowledged by community guidelines 
such as the NCCN (Engstrom 2007). Encouraging activity 
has also been observed in ﬁ  rst-line treatment in combina-
tion with FOLFIRI and FOLFOX, and when combined with 
regimens containing bevacizumab in patients with refrac-
tory disease. Accordingly, cetuximab – together with 5-FU, 
irinotecan, oxaliplatin, and bevacizumab – has emerged as 
one of the basic agents needed in overall mCRC manage-
ment. Additional clinical research is needed to determine 
the optimal combination and sequence of these agents for 
maximizing patient outcome, and the combination with beva-
cizumab in untreated patients deserves particular attention 
in light of the negative results obtained with the addition of 
the IgG2 panitumumab to bevacizumab plus FOLFOX. On 
the basis of available evidence, the best interactions appear 
when cetuximab is combined with oxaliplatin in ﬁ  rst-line 
treatment and with irinotecan in refractory disease. The rea-
son for this is unclear, but suggests that interactions between 
cetuximab and oxaliplatin involve different pathways than 
those between cetuximab and irinotecan. Ongoing studies, 
notably CALGB/SWOG 8405, are expected to provide 
important information regarding the best combinations of 
biologics with chemotherapy.
It is also particularly encouraging that cetuximab may 
enhance the curative opportunities in patients with early 
metastatic disease. Preliminary evidence suggests that add-
ing cetuximab to ﬁ  rst-line therapy may downstage disease 
in some patients, and as a result, allow potentially curative 
resection of previously unresectable metastases in approxi-
mately 20% of mCRC patients (Folprecht et al 2006; Andre 
et al 2007). Ongoing studies are also exploring whether 
the beneﬁ  ts of cetuximab extend earlier in the course of 
colorectal cancer into the adjuvant and neoadjuvant settings. 
As additional clinical results become available, the role of Biologics: Targets & Therapy 2007:1(2) 89
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cetuximab in management of mCRC as well as in earlier 
stages of disease should be more clearly understood.
Clearly, the selection of patients based on EGFR expres-
sion is no longer sufﬁ  cient, inasmuch as response rates appear 
independent of EGFR staining intensity (Cunningham et al 
2004; Lenz et al 2006). Moreover, patients whose tumors do 
not express EGFR have similar response rates as those with 
EGFR-expressing tumors (Chung et al 2005; Lenz et al 2006). 
This underscores the need to identify markers that predict 
response or resistance to cetuximab therapy. The observation 
that K-Ras gene mutation is associated with resistance to 
cetuximab is a promising ﬁ  rst step (Lievre et al 2006).
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